HISHOH Biopharma Co., Ltd.
HISHOH Biopharma develops next-generation allergen immunotherapy treatments aimed at achieving an allergy-free world. Their proprietary technology, HSO-001, is designed to rapidly and durably reduce antibody levels associated with hay fever. The company is also advancing sublingual immunotherapy, a form of desensitization therapy considered a potential curative treatment for Type I allergic diseases.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$2.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- HISHOH Biopharma develops next-generation allergen immunotherapy treatments aimed at achieving an allergy-free world. Their proprietary technology, HSO-001, is designed to rapidly and durably reduce antibody levels associated with hay fever. The company is also advancing sublingual immunotherapy, a form of desensitization therapy considered a potential curative treatment for Type I allergic diseases.